Cargando…

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on b...

Descripción completa

Detalles Bibliográficos
Autores principales: Niccoli, Laura, Nannini, Carlotta, Blandizzi, Corrado, Mantarro, Stefania, Mosca, Marta, Di Munno, Ombretta, Goletti, Delia, Benucci, Maurizio, Gobbi, Francesca Li, Cassarà, Emanuele, Kaloudi, Olga, Cantini, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207089/
https://www.ncbi.nlm.nih.gov/pubmed/30498353
http://dx.doi.org/10.2147/TCRM.S175772
_version_ 1783366479733850112
author Niccoli, Laura
Nannini, Carlotta
Blandizzi, Corrado
Mantarro, Stefania
Mosca, Marta
Di Munno, Ombretta
Goletti, Delia
Benucci, Maurizio
Gobbi, Francesca Li
Cassarà, Emanuele
Kaloudi, Olga
Cantini, Fabrizio
author_facet Niccoli, Laura
Nannini, Carlotta
Blandizzi, Corrado
Mantarro, Stefania
Mosca, Marta
Di Munno, Ombretta
Goletti, Delia
Benucci, Maurizio
Gobbi, Francesca Li
Cassarà, Emanuele
Kaloudi, Olga
Cantini, Fabrizio
author_sort Niccoli, Laura
collection PubMed
description OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD). METHODS: An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated. RESULTS: ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients. CONCLUSION: The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes.
format Online
Article
Text
id pubmed-6207089
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62070892018-11-29 Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables Niccoli, Laura Nannini, Carlotta Blandizzi, Corrado Mantarro, Stefania Mosca, Marta Di Munno, Ombretta Goletti, Delia Benucci, Maurizio Gobbi, Francesca Li Cassarà, Emanuele Kaloudi, Olga Cantini, Fabrizio Ther Clin Risk Manag Original Research OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD). METHODS: An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated. RESULTS: ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients. CONCLUSION: The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes. Dove Medical Press 2018-10-24 /pmc/articles/PMC6207089/ /pubmed/30498353 http://dx.doi.org/10.2147/TCRM.S175772 Text en © 2018 Niccoli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Niccoli, Laura
Nannini, Carlotta
Blandizzi, Corrado
Mantarro, Stefania
Mosca, Marta
Di Munno, Ombretta
Goletti, Delia
Benucci, Maurizio
Gobbi, Francesca Li
Cassarà, Emanuele
Kaloudi, Olga
Cantini, Fabrizio
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title_full Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title_fullStr Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title_full_unstemmed Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title_short Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
title_sort personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207089/
https://www.ncbi.nlm.nih.gov/pubmed/30498353
http://dx.doi.org/10.2147/TCRM.S175772
work_keys_str_mv AT niccolilaura personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT nanninicarlotta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT blandizzicorrado personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT mantarrostefania personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT moscamarta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT dimunnoombretta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT golettidelia personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT benuccimaurizio personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT gobbifrancescali personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT cassaraemanuele personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT kaloudiolga personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables
AT cantinifabrizio personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables